SCHEMBL2550138

SCHEMBL2550138

Cc1c[c]ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
NOTUM Q6P988 1/20 0.40
MYC P01106 1/20 0.37
CYP1A2 P05177 2/20 0.37
ALOX15 P16050 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
AKR1B10 O60218 1/20 0.37
TRPA1 O75762 1/20 0.37
ABCB11 O95342 1/20 0.37
DHFR P00374 1/20 0.37
LMNA P02545 1/20 0.37
MPO P05164 1/20 0.37
CHRM1 P11229 1/20 0.37
AKR1B1 P15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2553639 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDHSD17B10NOTUM
SCHEMBL6340582 0.83 SMN1; SMN2 (0.35) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL17672876 0.81 SIRT3 (0.41) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL490677 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10CYP1A2
SCHEMBL745395 0.78 SMN1; SMN2 (0.38) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL4288278 0.78 TSHR (0.41) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL744333 0.78 GAA (0.40) KDM4EHPGDHSD17B10GAAPOLB
SCHEMBL1406514 0.76 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10CYP1A2
SCHEMBL750508 0.74 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL6197923 0.74 KDM4E (0.44) ALDH1A1KDM4EHPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 US claimed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP claimed
WO-2017061957-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-04-13 WO claimed
EP-2552893-B1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-10-29 EP claimed
CN-102844305-B Antibacterial isoquinolin-3-ylurea derivatives ACTELION PHARMACEUTICALS LTD 2014-07-02 CN claimed
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives BUR DANIEL (CH) 2013-04-18 US claimed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 EP claimed
CN-102844305-A Antibacterial isoquinolin-3-ylurea derivatives ACTELION PHARMACEUTICALS LTD 2012-12-26 CN claimed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 WO claimed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 US disclosed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP disclosed
WO-2017061957-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-04-13 WO disclosed
WO-2017035114-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 WO disclosed
CN-105237655-A Marine organism polysaccharide Schiff base derivative, preparation method thereof, and application thereof as agricultural bactericide INST OCEANOLOGY CHINESE ACAD 2016-01-13 CN disclosed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 EP disclosed
CN-102844305-A Antibacterial isoquinolin-3-ylurea derivatives ACTELION PHARMACEUTICALS LTD 2012-12-26 CN disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 WO disclosed
US-6280900-B1 RADIATION SENSITIVE COMPOSITION WITH ALKALINE DEVELOPER SOLUBLE IN POLYMER COATED ON SUBSTRATE JSR CORPORATION (JP) 2001-08-28 US disclosed
US-4115643-A Process for 3-chloro cephalosporins ELI LILLY AND COMPANY (US) 1978-09-19 US disclosed
US-4031084-A Process for cephalosporin antibiotic intermediates ELI LILLY AND COMPANY (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS SMYD3, SMYD2, EHMT1 ALDH1A1 373/4885KDM4E 54/4885HPGD 2786/4885
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives CLIC1, IRF3, KCNH3 ALDH1A1 944/4885KDM4E 3201/4885HPGD 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.